AR006188A1 - "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion". - Google Patents

"composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".

Info

Publication number
AR006188A1
AR006188A1 ARP970100967A ARP970100967A AR006188A1 AR 006188 A1 AR006188 A1 AR 006188A1 AR P970100967 A ARP970100967 A AR P970100967A AR P970100967 A ARP970100967 A AR P970100967A AR 006188 A1 AR006188 A1 AR 006188A1
Authority
AR
Argentina
Prior art keywords
serinprotease
inhibit
activity
composition
prepare
Prior art date
Application number
ARP970100967A
Other languages
English (en)
Spanish (es)
Original Assignee
Aerovance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerovance Inc filed Critical Aerovance Inc
Publication of AR006188A1 publication Critical patent/AR006188A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • C07K14/8117Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
ARP970100967A 1996-03-11 1997-03-11 "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion". AR006188A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1310696P 1996-03-11 1996-03-11
US1979396P 1996-06-14 1996-06-14
US72525196A 1996-10-04 1996-10-04

Publications (1)

Publication Number Publication Date
AR006188A1 true AR006188A1 (es) 1999-08-11

Family

ID=27359773

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP970100967A AR006188A1 (es) 1996-03-11 1997-03-11 "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
ARP060101562A AR053063A2 (es) 1996-03-11 2006-04-20 Proteina sustancialmente purificada y composicion farmaceutica que la comprende
ARP070100116A AR058982A1 (es) 1996-03-11 2007-01-11 Vector de expresion de la proteina bicunina y metodo para producir dicha proteina

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP060101562A AR053063A2 (es) 1996-03-11 2006-04-20 Proteina sustancialmente purificada y composicion farmaceutica que la comprende
ARP070100116A AR058982A1 (es) 1996-03-11 2007-01-11 Vector de expresion de la proteina bicunina y metodo para producir dicha proteina

Country Status (27)

Country Link
US (3) US6583108B1 (instruction)
EP (1) EP0891426B1 (instruction)
JP (2) JP3469584B2 (instruction)
KR (1) KR100356956B1 (instruction)
AR (3) AR006188A1 (instruction)
AT (1) ATE328083T1 (instruction)
AU (1) AU716923B2 (instruction)
BR (1) BR9708021A (instruction)
CA (1) CA2247888A1 (instruction)
CO (1) CO4600683A1 (instruction)
DE (1) DE69735996T2 (instruction)
DK (1) DK0891426T3 (instruction)
ES (1) ES2263174T3 (instruction)
HR (1) HRP970144B1 (instruction)
HU (1) HU226419B1 (instruction)
ID (1) ID16224A (instruction)
IL (1) IL126115A (instruction)
IN (1) IN192874B (instruction)
MY (1) MY120693A (instruction)
NZ (1) NZ331540A (instruction)
PA (1) PA8426301A1 (instruction)
PL (1) PL188387B1 (instruction)
PT (1) PT891426E (instruction)
SV (1) SV1997000018A (instruction)
TR (1) TR199801794T2 (instruction)
WO (1) WO1997033996A2 (instruction)
YU (1) YU8997A (instruction)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE69632435T2 (de) * 1995-07-24 2005-05-12 Mitsubishi Chemical Corp. Inhibitor des Hepatozytwachstumsfaktoraktivators
PT891426E (pt) 1996-03-11 2006-10-31 Bayer Corp Bicunina humana
AU6042298A (en) * 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
CN1229138C (zh) * 1998-12-22 2005-11-30 拜尔公开股份有限公司 加速粘液纤毛的清除速率的方法
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
AU3731400A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
IL140993A0 (en) 2000-05-15 2002-02-10 Bayer Ag Trypsin substrate and diagnostic device, and method of using same
IL140994A (en) * 2000-05-15 2005-12-18 Bayer Ag Urinary trypsin inhibitor assay containing a chelating agent
US6955921B2 (en) * 2001-04-30 2005-10-18 Bayer Corporation Trypsin substrate and diagnostic device, and method of using same
WO2003040330A2 (en) * 2001-11-05 2003-05-15 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
BRPI0406647A (pt) 2003-01-06 2005-12-06 Angiochem Inc Método para transportar um composto através da barreira sanguìnea do cérebro
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
WO2005019434A2 (en) 2003-08-26 2005-03-03 The Regents Of The University Of Colorado, A Body Corporate Serine protease inhibitors for treatment of bacterial infections
AU2004280238A1 (en) * 2003-10-10 2005-04-21 Multicell Technologies, Inc. Use of cell lines to produce active therapeutic proteins
EP1675874A1 (en) * 2003-10-16 2006-07-05 Bayer HealthCare LLC Monoclonal antibodies for detection of urinary trypsin inhibitors
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
EP1810185A4 (en) 2004-06-04 2010-01-06 Therasense Inc DIABETES SUPPLY HOST CLIENT ARCHITECTURE AND DATA MANAGEMENT SYSTEM
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
SI2360258T1 (sl) 2005-02-18 2015-02-27 Angiochem Inc. Polipeptidi aprotinina za prenos spojine preko krvno-moĹľganske pregrade
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
RU2422143C2 (ru) 2005-07-15 2011-06-27 Анджиокем Инк. Усиление действия противораковых агентов
US8093017B2 (en) * 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
AU2006332774A1 (en) * 2005-12-29 2007-07-12 Dyax Corp. Protease inhibition
US8063012B2 (en) * 2006-09-19 2011-11-22 Phylogica Limited Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor
WO2008058167A2 (en) * 2006-11-07 2008-05-15 Case Western Reserve University Method for treating disorders associated with complement activation
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2170932A4 (en) * 2007-06-20 2012-10-10 Phylogica Ltd COMPOSITIONS AND APPLICATIONS THEREOF IN THE TREATMENT OF ACUTE ATOMIC SYNDROME (ARDS) AND ASSOCIATED CLINICAL ILLNESSES
JP2010536870A (ja) * 2007-08-21 2010-12-02 ジェンザイム・コーポレーション カリクレイン阻害剤を用いた治療
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
CN102026667B (zh) * 2008-04-18 2014-06-25 安吉奥开米公司 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CN102245636A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 用于药物递送的依托泊苷和多柔比星结合物
AU2009322043A1 (en) 2008-12-05 2011-07-07 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2373789A4 (en) 2008-12-17 2012-08-29 Angiochem Inc MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
MX2011011023A (es) 2009-04-20 2012-01-20 Angiochem Inc Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2.
MX2012000016A (es) 2009-07-02 2012-03-26 Angiochem Inc Conjugados de peptidos multimericos y sus usos.
HRP20220107T1 (hr) 2010-01-06 2022-04-15 Takeda Pharmaceutical Company Limited Proteini koji vežu kalikrein plazme
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp KALLIKREIN PLASMA BINDING PROTEINS
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
EP2723370A4 (en) 2011-06-24 2015-06-03 Univ Colorado Regents COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
KR20140137347A (ko) 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
US9687561B2 (en) 2012-08-14 2017-06-27 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
US9856310B2 (en) 2014-02-24 2018-01-02 Takeda Pharmaceutical Company Limited UTI fusion proteins
JP6719384B2 (ja) 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
CO2018007151A2 (es) 2015-12-11 2018-09-20 Dyax Corp Inhibidores de calicreína plasmática y usos de los mismos para tratar ataque de angioedema hereditario
US11725043B2 (en) 2020-03-05 2023-08-15 DiaMedica USA Inc. Ulinastatin polypeptides

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
EP0401508B1 (de) 1989-05-13 1994-11-23 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
DK0439442T3 (da) 1990-01-25 1996-07-08 Univ Washington Faktor X-LACI-hybridprotein
DE573603T1 (de) 1991-03-01 1999-05-06 Dyax Corp., Cambridge, Mass. Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g.
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
EP0651766A4 (en) 1992-07-13 1996-07-31 Corvas Int Inc INHIBITORS OF FACTOR Xa, DERIVED FROM THE INHIBITOR OF THE PANCREATIC TRYPSON FROM BEEF.
US5436153A (en) 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
AU5684594A (en) 1992-12-02 1994-06-22 Novo Nordisk A/S Novel human amyloid protein precursor homologue and kunitz-type inhibitors
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
CA2180954C (en) 1994-01-11 2007-03-20 William Markland Inhibitors of human plasmin derived from the kunitz domains
JP3805785B2 (ja) 1994-01-11 2006-08-09 ダイアックス コープ. カリクレイン阻害クニッツドメイン蛋白質およびその相同体
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
WO1996003503A1 (fr) 1994-07-21 1996-02-08 The Green Cross Corporation Procede de production d'un inhibiteur de la trypsine urinaire et des domaines de celui-ci, nouveau polypeptide associe et procede de production de ce polypeptide
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
CA2220497A1 (en) 1995-05-08 1996-11-14 Scios, Inc. Kunitz type protease inhibitors
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
DE69632435T2 (de) 1995-07-24 2005-05-12 Mitsubishi Chemical Corp. Inhibitor des Hepatozytwachstumsfaktoraktivators
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
PT891426E (pt) 1996-03-11 2006-10-31 Bayer Corp Bicunina humana
AU6042298A (en) 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity

Also Published As

Publication number Publication date
CA2247888A1 (en) 1997-09-18
US7019123B2 (en) 2006-03-28
PA8426301A1 (es) 2000-05-24
TR199801794T2 (xx) 2000-07-21
JP2001521367A (ja) 2001-11-06
EP0891426A2 (en) 1999-01-20
IL126115A0 (en) 1999-05-09
HRP970144A2 (en) 1998-04-30
BR9708021A (pt) 1999-07-27
IN192874B (instruction) 2004-05-29
DE69735996T2 (de) 2007-02-15
NZ331540A (en) 1999-10-28
WO1997033996A2 (en) 1997-09-18
US7452859B2 (en) 2008-11-18
ID16224A (id) 1997-09-11
HRP970144B1 (en) 2004-10-31
US20060172946A1 (en) 2006-08-03
AR058982A1 (es) 2008-03-05
AU716923B2 (en) 2000-03-09
IL126115A (en) 2007-03-08
HUP9902698A3 (en) 2001-06-28
YU8997A (sh) 1999-09-27
AR053063A2 (es) 2007-04-18
SV1997000018A (es) 1999-01-14
US6583108B1 (en) 2003-06-24
WO1997033996A3 (en) 1997-11-13
US20030194398A1 (en) 2003-10-16
HU226419B1 (en) 2008-12-29
MY120693A (en) 2005-11-30
PT891426E (pt) 2006-10-31
ES2263174T3 (es) 2006-12-01
CO4600683A1 (es) 1998-05-08
JP3469584B2 (ja) 2003-11-25
DK0891426T3 (da) 2006-10-02
KR19990087697A (ko) 1999-12-27
EP0891426B1 (en) 2006-05-31
KR100356956B1 (ko) 2003-03-15
JP2004000208A (ja) 2004-01-08
PL328822A1 (en) 1999-02-15
ATE328083T1 (de) 2006-06-15
PL188387B1 (pl) 2005-01-31
DE69735996D1 (de) 2006-07-06
AU2207797A (en) 1997-10-01
HUP9902698A2 (hu) 1999-11-29

Similar Documents

Publication Publication Date Title
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DE60144145D1 (de) Subtilisin-variante
AR008727A1 (es) COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO
DK0506884T3 (da) Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
NO960309L (no) Agonister og antagonister for humaninterleukin-10
DK0479948T3 (da) Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
GB9722320D0 (en) Human cell cycle checkpoint proteins
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
BR0010563A (pt) Composições isoladas de células da pele e métodos para seu uso
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
LTIP610A (en) Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
BR0110394A (pt) Proteìna anti-congelamento, sequência nucleica, vetor, método para produzir uma proteìna anti-congelamento, organismo geneticamente modificado, extrato contendo proteìna, e, produto alimentìcio
DK0769056T3 (da) Ikke-splejsende verianter af gp350/220
DK0805204T3 (da) Bitestikel - specifikt receptorprotein og anvendelse heraf
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ECSP972054A (es) Bicunina humana
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
EA199801032A1 (ru) Белки zona pellucida для контрацепции
SE9604439D0 (sv) New receptor
TH62241A (th) ไบคูนินของคน

Legal Events

Date Code Title Description
FG Grant, registration